• Raymond James sets a new price target of $21 for NASDAQ:WVE, suggesting a potential increase of 13.39% from the current price.
• Wave Life Sciences announces a public offering valued at $250 million, including ordinary shares and pre-funded warrants.
• The stock has experienced a remarkable increase of 147.26%, with today's price fluctuating between $12.72 and $19.54.

Wave Life Sciences Ltd. (NASDAQ: WVE) is a clinical-stage biotechnology company focused on developing innovative therapies for genetic diseases. On December 8, 2025, Raymond James set a new price target of $21 for WVE, which was trading at $18.52 at the time. This target suggests a potential increase of 13.39% from the current price.

Wave Life Sciences recently announced a public offering valued at $250 million. This offering includes ordinary shares and pre-funded warrants, providing flexibility for investors. The company also plans to offer underwriters a 30-day option to purchase an additional 15% of the total shares and shares underlying pre-funded warrants.

The stock has seen a remarkable increase of 147.26%, with a change of $11.03. Today, WVE's price fluctuated between $12.72 and $19.54, reaching its highest point in the past year. The lowest price for the year was $5.28, indicating significant growth over the period.

WVE's market capitalization stands at approximately $3.04 billion, reflecting its substantial presence in the biotechnology sector. The trading volume today is 143.9 million shares, highlighting strong investor interest. The joint book-running managers for the public offering are Jefferies, Leerink Partners, and BofA Securities.